Forbes June 26, 2024
Ozempic and Wegovy are having an unintended but not entirely unpredictable effect on the apparel industry. Impact Analytics, an AI-based planning and forecasting company, found that the GLP-1 drugs, which are typically prescribed for diabetes but are used by millions for weight loss, are driving down sizes in department and specialty stores. And the issue has implications all along the supply chain.
“It’s something that retailers need to monitor,” Impact Analytics founder and CEO Prashant Agrawal said. “It’s a sustainability issue. We can’t make things that won’t get used.”
The Impact Analytics report connects the dots between Ozempic and Wegovy use and clothing sizes and cites the effect of diminishing clothing measurements on retail profit margins.
“The slimming down of...
Today's Sponsors
Today's Sponsor